News

Opinion Leaders in Rheumatology

For decades, rheumatology accepted steroid damage as the price of controlling disease. The clinicians interviewed here built the modern steroid-toxicity argument against that assumption. They reached the same conclusion from different starting points: steroid-toxicity is measurable end-organ damage, and the field now has the instruments to track it.


Their vantage points span giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), lupus, vasculitis, rheumatoid arthritis (RA), and the research infrastructure that connects them.


GCA and PMR: dose reduction is not toxicity reduction

Historically, the most consequential belief about steroids in clinical trial design has been that dose reduction is a proxy for reduced harm. Two respected experts in GCA and PMR have spent their careers trying to close that gap.


Frank Buttgereit, MD, Professor of Rheumatology and Deputy Head of the Department of Rheumatology and Clinical Immunology at the Charité University Medicine in Berlin, puts the arithmetic plainly:


"Every milligram that helps control the disease is a good milligram, but every milligram we can spare is an even better one."


He was among the international subspecialty experts who co-developed the Glucocorticoid Toxicity Index (GTI),[1] and he argues the instrument matters precisely because it captures cumulative toxicity across domains that a dose-reduction number cannot see. Buttgereit's position on GCA and PMR management aligns with his broader thesis: the goal is a measurable reduction in the organ-level harm that every milligram of long-term steroid exposure carries, which a dose count alone cannot show.


Max Hamburger, MD, an American College of Rheumatology Master and founder of United Rheumatology, has watched the steroid paradox play out across more than 40 years of private practice. He is direct about the mechanism of harm:


"Sadly it didn't take long for physicians to discover that steroid-toxicity is almost linearly related to the potential value of these drugs."


What makes his perspective distinctive is his focus on the patient side of that equation. By the time a patient is experiencing side effects, Hamburger observes, the physical changes, whether cataracts, bone loss, or new-onset diabetes, have already occurred.


"While some steroid-toxicities can be mitigated by tapering the drug back, a lot of the side effects are very long-lasting. Steroids are like radiation, the best amount of exposure is no exposure."


Hamburger sees the GTI as a tool that makes this risk concrete enough for patients to act on, giving them a number they can track as doses change.


Lupus: where the damage was always the steroids

In lupus, the steroid-toxicity case has been made with some of the most rigorous longitudinal data in all of rheumatology.


Michelle Petri, MD MPH, Professor of Medicine at the Johns Hopkins University School of Medicine and Director of the Hopkins Lupus Cohort, has spent decades tracking what the Hopkins data actually show: 15 years after a lupus diagnosis, 80% of permanent organ damage is attributable to steroids.[2] The Hopkins Lupus Cohort is one of the largest longitudinal studies of morbidity and mortality in lupus in the world, and its findings on maintenance dosing are stark. Just 6 milligrams of daily prednisone is enough to increase permanent later organ damage; at 10 milligrams the data show a twofold rise in myocardial infarction and stroke.[2] Her published position on prescribing culture is unambiguous:


"There has to be an acceptance that steroids are now an undesirable part of treating most rheumatic diseases, and our prescribing behavior must change."


Vasculitis: the field that proved the regulatory case

David Jayne, MD is among the leading voices in ANCA-associated vasculitis (AAV), a disease that spent four decades managing inflammation with regimens that also generated substantial cumulative steroid-toxicity. Updated EULAR AAV recommendations have expanded steroid-sparing options in the disease. Jayne has argued that vasculitis is a proof case for the whole field: when a trial measures toxicity reduction directly as an endpoint, the regulatory and clinical conversation changes. His perspective connects directly to our coverage of steroid-toxicity in ANCA-associated vasculitis and the EULAR guidance update.


RA and drug development: the culture problem

The voices most focused on RA and the drug-development pipeline converge on a different version of the same problem: steroid prescribing culture is what holds the field back.


Andreas Reiff, MD, Senior Vice President and Global Therapeutic Area Head for inflammation and immunology at Parexel and a board-certified rheumatologist and pediatrician, argues the damage extends beyond patients to the clinical research that should be finding their replacements.


"Nobody disputes the value of glucocorticoids, and while most clinicians recognize the damage they cause to patients, they don't recognize the impact they have on clinical research."


Reiff's position is that drugs die in development partly because they are tested against a background contaminated by concurrent steroid use, and that trial protocols now demanding aggressive taper and sustained discontinuation are the correct response. He has watched three waves of immunology innovation and describes the current wave as the first to seriously pursue steroid elimination.


Yoshiya Tanaka, MD, PhD, President of the Japanese Association of Clinical Immunology and the author of nearly 600 publications in systemic autoimmune and rheumatic disease, offers a perspective on how measurement changes clinical behavior at the practitioner level. Every patient under his team's care is assessed for steroid-toxicity using the GTI, and he is in the process of writing new Japanese treatment guidelines that embed GTI monitoring as a standard of care element. His view on taper decisions is practical:


"We know that it is not easy to taper patients safely. So if we find a patient's toxicity scores are worsening we can try an immunosuppressant or a biologic drug and then we need to track to see if we can taper the glucocorticoids safely."


That sentence describes what structured measurement enables: an evidence-based rationale for a switch decision.


Ewa Olech, MD adds the perspective of a rheumatologist engaged with steroid-toxicity measurement in routine clinical practice, showing that the GTI belongs in routine clinic encounters as much as in clinical trials.


The patient voice in rheumatology

Kathy Perez, Founder of KP Advocacy and Policy and a veteran of more than 25 product launches in rare disease and oncology, brings into focus what the clinical data leave out. She has documented the patient-level experience of chronic steroid use across rheumatic diseases and frames it directly:


"When patients can track their own experience of steroid-toxicity and take that data straight into the clinic, they stop being passive recipients and start driving the conversation."


Measurement as the standard of care

Together these conversations span GCA, PMR, lupus, vasculitis, RA, and the patient experience that cuts across all of them. The physicians and advocates gathered here hold different clinical specializations, work in different health systems, and have arrived at their positions through different bodies of evidence. The conclusion is the same in every case: steroid-toxicity is quantifiable, the instruments to quantify it exist, and the field is past the point where treating it as an unavoidable side effect is defensible.


Measurement is what changes the clinical decision. When a GTI score worsens, a taper decision has an evidence base. When lupus damage is tracked against steroid exposure at the Hopkins Cohort scale, the prescribing conversation changes. When a vasculitis trial captures toxicity alongside efficacy, the regulatory submission is stronger. The direction of travel across rheumatology is toward standardized, validated measurement of steroid-toxicity as part of routine care. The clinicians and researchers featured here are among the people who built that direction.


For the foundational measurement arguments, read this related article on the Steroid Stewardship Hub.


References

  1. Miloslavsky EM, Naden RP, Bijlsma JWJ et al. Development of the Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann. Rheum. Dis. (2017). 76:543-546. https://doi.org/10.1136/annrheumdis-2016-210002

  2. Joo YB, Won S, Choi C-B and Bae S-C. Lupus nephritis is associated with more corticosteroid-associated organ damage but less corticosteroid non-associated organ damage. Lupus 26:598-605, 2017. https://doi.org/10.1177/0961203316671813


Categories: